The symptom burden of primary brain tumors: Evidence for a core set of tumor-and treatment-related symptoms

Neuro-Oncology

Volumn 18, Issue 2, 2016, Pages 252-260

  Armstrong, Terri S ^a   Vera Bolanos, Elizabeth ^b   Acquaye, Alvina A ^b   Gilbert, Mark R ^b   Ladha, Harshad ^a   Mendoza, Tito ^b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

clinical outcomes assessment; patient reported outcomes; symptoms

Indexed keywords

ADULT; AGED; ARTICLE; BRAIN TUMOR; CANCER PAIN; CANCER PATIENT; CANCER RECURRENCE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE SEVERITY; DISTRESS SYNDROME; DROWSINESS; DYSPHASIA; DYSPNEA; FATIGUE; FEMALE; GLIOMA; HEMIPARESIS; HUMAN; IRRITABILITY; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; MALE; MEMORY DISORDER; NAUSEA; OUTCOME ASSESSMENT; PREVALENCE; PRIMARY TUMOR; SADNESS; SLEEP DISORDER; SYMPTOM; SYMPTOM ASSESSMENT; TREATMENT RELATED SYMPTOM; TUMOR RELATED SYMPTOM; VOMITING; XEROSTOMIA; ADOLESCENT; ADVERSE DRUG REACTION; BRAIN NEOPLASMS; CANCER GRADING; FOLLOW UP; META ANALYSIS (TOPIC); MIDDLE AGED; PROGNOSIS; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TUMOR RECURRENCE; VERY ELDERLY; YOUNG ADULT;

ANTINEOPLASTIC AGENT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; META-ANALYSIS AS TOPIC; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; SYMPTOM ASSESSMENT; YOUNG ADULT;

EID: 84960396445     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nov166     Document Type: Article

References (22)

1. Cleeland CS, Zhao F, Chang VT, et al. The symptom burden of cancer: Evidence for a core set of cancer-related and treatment-related symptoms from the Eastern Cooperative Oncology Group Symptom Outcomes and Practice Patterns study. Cancer. 2013;119(24):4333-4340.
2. Armstrong TS, Cohen MZ, Eriksen LR, Hickey JV. Symptom clusters in oncology patients and implications for symptom research in people with primary brain tumors. J Nurs Scholarsh. 2004;36(3): 197-206.
3. Armstrong TS, Mendoza T, Gning I, et al. Validation of the M.D. Anderson Symptom Inventory Brain Tumor Module (MDASI-BT). J Neurooncol. 2006;80(1):27-35.
4. Armstrong TS,Wefel JS,Wang M, et al. Net clinical benefit analysis of radiation therapy oncology group 0525: a phase III trial comparing conventional adjuvant temozolomide with doseintensive temozolomide in patients with newly diagnosed glioblastoma. J Clin Oncol. 2013;31(32):4076-4084.
5. Armstrong TS, Vera-Bolanos E, Gning I, et al. The impact of symptom interference using the MD Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT) on prediction of recurrence in primary brain tumor patients. Cancer. 2011; 117(14):3222-3228.
6. Cleeland CS, Sloan JA, ASPCRO Organizing Group. Assessing the Symptoms of Cancer Using Patient-Reported Outcomes (ASCPRO): searching for standards. J Pain Symptom Manage. 2010;39(6):1077-1085.
7. Basch E, Reeve BB, Mitchell SA, et al. Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). J Natl Cancer Inst. 2014;106(9):1-11.
8. Basch E, Abernethy AP, Mullins CD, et al. Recommendations for incorporating patient-reported outcomes into clinical comparative effectiveness research in adult oncology. J Clin Oncol. 2012; 30(34):4249-4255.
9. Shih YC, Ganz PA, Aberle D, et al. Delivering high-quality and affordable care throughout the cancer care continuum. J Clin Oncol. 2013;31(32):4151-4157.
10. American Society of Clinical Oncology. The state of cancer care in America, 2014: a report by the American Society of Clinical Oncology. J Oncol Pract. 2014;10(2):119-142.
11. Esther Kim JE, Dodd MJ, Aouizerat BE, Jahan T, Miaskowski C. A review of the prevalence and impact of multiple symptoms in oncology patients. J Pain Symptom Manage. 2009;37(4):715-736.
12. Reilly CM, Bruner DW, Mitchell SA, et al. A literature synthesis of symptom prevalence and severity in persons receiving active cancer treatment. Support Care Cancer. 2013;21(6):1525-1550.
13. Reeve BB, Mitchell SA, Dueck AC, et al. Recommended patient-reported core set of symptoms to measure in adult cancer treatment trials. J Natl Cancer Inst. 2014;106(7):1-7.
14. Palos GR, Mendoza TR, Mobley GM, Cantor SB, Cleeland CS. Asking the community about cutpoints used to describe mild, moderate, and severe pain. J Pain. 2006;7(1):49-56.
15. Armstrong TS,Wefel JS, Gning I, et al. Congruence of primary brain tumor patient and caregiver symptom report. Cancer. 2012; 118(20):5026-5037.
16. Seow H, Sussman J, Martelli-Reid L, Pond G, Bainbridge D. Do high symptom scores trigger clinical actions? An audit after implementing electronic symptom screening. J Oncol Pract. 2012;8(6):e142-e148.
17. Kayl AE, Meyers CA. Does brain tumor histology influence cognitive function? Neuro Oncol. 2003;5(4):255-260.
18. Armstrong TS, Cron SG, Bolanos EV, Gilbert MR, Kang DH. Risk factors for fatigue severity in primary brain tumor patients. Cancer. 2010;116(11):2707-2715.
19. Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014;370(8):699-708.
20. Struik K, Klein M, Heimans JJ, et al. Fatigue in low-grade glioma. J Neurooncol. 2009;92(1):73-78.
21. York MK, Rettig GM, Grossman RG, et al. Seizure control and cognitive outcome after temporal lobectomy: a comparison of classic Ammon's horn sclerosis, atypical mesial temporal sclerosis, and tumoral pathologies. Epilepsia. 2003;44(3):387-398.
22. Mirsattari SM, Chong JJ, Hammond RR, et al. Do epileptic seizures predict outcome in patients with oligodendroglioma? Epilepsy Res. 2011;94(1-2):39-44.